MA37829A1 - Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha - Google Patents
Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alphaInfo
- Publication number
- MA37829A1 MA37829A1 MA37829A MA37829A MA37829A1 MA 37829 A1 MA37829 A1 MA 37829A1 MA 37829 A MA37829 A MA 37829A MA 37829 A MA37829 A MA 37829A MA 37829 A1 MA37829 A1 MA 37829A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- egfr
- optionally
- raf
- pharmaceutical combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
L'invention concerne une combinaison pharmaceutique comprenant (a) un inhibiteur de b-raf, (b) un inhibiteur d'egfr et facultativement (c) un inhibiteur de pi3k ; les utilisations d'une telle combinaison dans le traitement de maladies de prolifération ; et des méthodes de traitement d'un sujet souffrant d'une maladie de prolifération comprenant l'administration d'une quantité thérapeutiquement efficace d'une telle combinaison.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680473P | 2012-08-07 | 2012-08-07 | |
PCT/US2013/053619 WO2014025688A1 (fr) | 2012-08-07 | 2013-08-05 | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha |
Publications (1)
Publication Number | Publication Date |
---|---|
MA37829A1 true MA37829A1 (fr) | 2017-01-31 |
Family
ID=48980368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37829A MA37829A1 (fr) | 2012-08-07 | 2015-02-04 | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha |
Country Status (39)
Country | Link |
---|---|
US (1) | US9474754B2 (fr) |
EP (2) | EP2882440B1 (fr) |
JP (3) | JP6342396B2 (fr) |
KR (1) | KR102112885B1 (fr) |
CN (1) | CN104519887B (fr) |
AR (1) | AR092045A1 (fr) |
AU (1) | AU2013299841B8 (fr) |
CA (1) | CA2879548C (fr) |
CL (1) | CL2015000294A1 (fr) |
CO (1) | CO7200273A2 (fr) |
CY (1) | CY1122143T1 (fr) |
DK (1) | DK2882440T3 (fr) |
EA (1) | EA028420B1 (fr) |
EC (1) | ECSP15008695A (fr) |
ES (1) | ES2717911T3 (fr) |
GT (1) | GT201500025A (fr) |
HK (2) | HK1204976A1 (fr) |
HR (1) | HRP20190537T1 (fr) |
HU (1) | HUE042877T2 (fr) |
IL (1) | IL236934B (fr) |
IN (1) | IN2015DN00450A (fr) |
JO (1) | JOP20130236B1 (fr) |
LT (1) | LT2882440T (fr) |
MA (1) | MA37829A1 (fr) |
MX (1) | MX359403B (fr) |
MY (1) | MY176031A (fr) |
NZ (1) | NZ703940A (fr) |
PE (2) | PE20191655A1 (fr) |
PH (1) | PH12015500246B1 (fr) |
PL (1) | PL2882440T3 (fr) |
PT (1) | PT2882440T (fr) |
RS (1) | RS58734B1 (fr) |
SG (1) | SG11201500321YA (fr) |
SI (1) | SI2882440T1 (fr) |
TN (1) | TN2015000027A1 (fr) |
TR (1) | TR201904980T4 (fr) |
TW (1) | TWI607754B (fr) |
UA (1) | UA115786C2 (fr) |
WO (1) | WO2014025688A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9474754B2 (en) * | 2012-08-07 | 2016-10-25 | Novartis Ag | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
MX2015013466A (es) | 2013-03-21 | 2016-06-21 | Novartis Ag | Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor. |
WO2015145388A2 (fr) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt |
AU2015276309B2 (en) * | 2014-06-16 | 2021-06-17 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
WO2016193955A1 (fr) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinaisons d'inhibiteurs de kinase pour le traitement du cancer colorectal |
EP3380097A2 (fr) * | 2015-08-28 | 2018-10-03 | Novartis AG | Combinaison pharmaceutique comprenant (a) l'inhibiteur au pi3k isoforme-alpha spécifique alpelisib (byl719) et (b) un inhibiteur à akt, de préférence mk-2206, afuresertib ou uprosertib, et son utilisation dans le traitement/la prévention du cancer |
JP2018525402A (ja) * | 2015-08-28 | 2018-09-06 | ノバルティス アーゲー | Pi3k阻害剤のアルペリシブおよびb−raf阻害剤のダブラフェニブを含む組合せ医薬、がんの治療または予防におけるそのような組合せの使用 |
WO2017066664A1 (fr) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Polythérapie comprenant un inhibiteur de raf pour le traitement du cancer colorectal |
WO2017210538A1 (fr) | 2016-06-03 | 2017-12-07 | Giordano Caponigro | Combinaisons pharmaceutiques |
JP7114575B2 (ja) * | 2016-09-19 | 2022-08-08 | ノバルティス アーゲー | Raf阻害剤及びerk阻害剤を含む治療用組合せ |
SG11201913249SA (en) * | 2017-08-03 | 2020-02-27 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
FI3860998T3 (fi) | 2018-10-05 | 2024-03-27 | Annapurna Bio Inc | Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon |
TW202043225A (zh) * | 2019-01-25 | 2020-12-01 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
WO2020164997A1 (fr) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combinaison d'inhibiteurs de la pi3k |
WO2023145530A1 (fr) * | 2022-01-27 | 2023-08-03 | 国立大学法人東北大学 | Agent thérapeutique contre le cancer |
WO2023230554A1 (fr) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf |
WO2024073364A1 (fr) * | 2022-09-26 | 2024-04-04 | Beigene, Ltd. | Associations d'un inhibiteur de b-raf et d'un anticorps anti-egfr pour le traitement du cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EA020022B1 (ru) | 2007-04-10 | 2014-08-29 | Экселиксис, Инк. | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
IN2012DN01403A (fr) * | 2009-08-24 | 2015-06-05 | Genentech Inc | |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
EP2488184A4 (fr) * | 2009-10-12 | 2013-04-24 | Glaxosmithkline Llc | Combinaison |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
EP2637661B1 (fr) * | 2010-11-08 | 2017-12-20 | Novartis AG | Utilisation de la 1-({4-méthyl-5-[2-(2,2,2-trifluoro- 1,1-diméthyléthyl)- pyridin-4-yl]thiazole-2-yl}-amide) du 2-amide de l'acide (S)-pyrrolidine-1,2-dicarboxylique dans le traitement de maladies dépendantes d'EGFR ou de maladies qui ont acquis une résistance aux agents qui ciblent des membres de la famille d'EGFR |
US20140275174A1 (en) | 2011-11-10 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
CN108542906A (zh) * | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
US9474754B2 (en) * | 2012-08-07 | 2016-10-25 | Novartis Ag | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
-
2013
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/fr active Active
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active IP Right Grant
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 CA CA2879548A patent/CA2879548C/fr active Active
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/fr active Pending
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/fr active Application Filing
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 PH PH12015500246A patent/PH12015500246B1/en unknown
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
- 2015-06-18 HK HK15105815.5A patent/HK1204976A1/xx unknown
- 2015-11-03 HK HK15110834.2A patent/HK1211831A1/xx unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-03-19 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
MA39094B1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
MA34815B1 (fr) | Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer | |
EA033448B1 (ru) | Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
EA201000990A1 (ru) | Лечение дисменореи путем трансдермального введения нестероидных противовоспалительных лекарственных средств | |
EA201200443A1 (ru) | Комбинированное лекарственное средство и способ лечения венозных церебральных дисциркуляций | |
MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses | |
MA37957A1 (fr) | Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées | |
MA35927B1 (fr) | Polythérapie pour le traitement d'un cancer de l'ovaire | |
MA38056A1 (fr) | Inhibiteurs de la tyrosine kinase de bruton |